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SYNOVIAL JOINT ANATOMY AND PHYSIOLOGY
Before discussing osteoarthritis (OA) in companion animals, one must understand the
synovial joint anatomy and physiology of an animal. The synovial joint is the most common joint
and most complex type of joint found in the body. It contains synovial fluid that has three
primary functions: lubrication, nutrient distribution, and shock absorption. This fluid is found in
the synovial cavity of a joint, which is the space enclosed by the articular capsule. The articular
capsule is a fibrous capsule that is continuous with the periosteum of articulating bones. It
consists of two layers; the outer fibrous layer and the inner synovial layer. The outer fibrous
layer is made up of white fibrous tissue, called the capsular ligament. Its role is to hold together
articulating bones and support the synovium. The synovium is the inner synovial layer, a highly
vascularized layer of connective tissue. It absorbs and secretes synovial fluid, and is responsible
for the mediation of nutrient exchange between circulating blood and the joint. The bones of a
synovial joint are covered by a thin layer of hyaline cartilage, which serves to line the epiphysis
of the bone. The cartilage provides a smooth surface and has two functions; it minimizes friction
upon joint movement and absorbs shock.
Capsular ligaments are another important part of the synovial joint. They are made up of
bundles of dense connective tissue that are highly adapted for resisting strain to prevent extreme
movements that may damage articulation. Dense connective tissue consists predominately of
extracellular matrix (ECM) and the ECM contains a multitude of structural fibers. These
structural fibers are made up of crossed linked fibrillar proteins, hydrated gelatinous interfibrillar
matrix containing an array of nonfibrillar proteins, proteoglycans (PGs), glycoproteins,
proteolipids, and polysaccharides. Furthermore, connective tissue also contains cells called
progenitor cells. These cells, represented in small numbers, play an important role in repair,
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regeneration, and adaptive modeling of connective tissues. Next, a bursa is a small sac lined by
the synovial membrane and filled with synovial fluid. They are placed at key points of friction in
a joint, providing the joint with free movement. They can become inflamed following infection
or irritation by over-use of the joint. Joints have a rich nerve supply provided by articular nerves.
The nerves of a joint transmit impulses which play a key role in proprioception. Furthermore,
joints receive blood through articular arteries, which arise from the vessels around the joint. The
articular arteries are located within the joint capsule, mostly in the synovial membrane. A
common feature of the articular arterial supply is frequent anastomoses by collateral channels in
order to ensure blood flow to and across the joint regardless of position of joint. The articular
veins accompany the articular arteries and are also found in the synovial membrane.
The molecular components of ECM are collagen, elastin, and proteoglycans. Collagen is
the most abundant protein in the body. There are several groups of collagens, but of primary
importance are the fibrillar collagens. Fibrillar collagens make up the major structural
components of connective tissues such as tendons, ligament, cartilage, and bone. There are three
different types labeled; type I, type II, and type III. Type I collagen forms linearly and has
extensively crossed-linked macromolecular structures that impart high tensile strength to tendons
and ligaments (Zink and Van Dyke, 2013). Type II collagen fibrils with articular cartilage are
cross-linked into extensive three-dimensional networks that provide resistance to deformation in
a multitude of directions (Zink and Van Dyke, 2013). Furthermore, tendons, ligaments, joint
capsule, bone, and articular cartilage all contain an important component called elastin. Elastin
provides tissues with elasticity, which refers to the ability of a tissue to undergo reversible
deformation. The amount of these components in different tissues varies greatly depending on
the requirement for elasticity. Bone contains minimal amounts of elastin, while it is particularly
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abundant within the ECM of structures that undergo repeated cycles of elongation and elastic
recoil. Such structures with an abundance of elastin are joint capsules or the nuchal ligament.
Elastic fibers are tremendously durable and can withstand up to a 200% increase in length from
the resting state. With this stated, elastic fibers are capable of practically unlimited numbers of
cycles of elongation and elastic recoil without loss of strength. Elastin is produced mostly during
growth, but is also produced during the repair and remodeling phases of tissue healing.
Proteoglycans are glycosylated proteins that are components of ECM of all the
connective tissues. The PGs consists of a core protein to which a number of glycosaminoglycan
(GAG) side chains are covalently attached. The core proteins fluctuate greatly in length and
amino acid sequence. Glycosaminoglycan side chains are long, linear polysaccharide polymers
composed of repeating disaccharide units. There are several classes of PGs, but the PGs of most
interest are the aggregating PGs and the small leucine-rich PGs (SLRPs). The aggregating PGs
include, aggrecan, versican, brevican, neurocan, and are massive macromolecular complexes.
Their high degree of hydration underlies the turgidity and resistance to compression in several
tissues such as hyaline articular cartilage, meniscal fibrocartilage, and the nucleus pulposus of
the intervertebral disk (Zink and Van Dyke, 2013). Small leucine-rich proteoglycans are
associated with fibrillar elements of the ECM such as collagen and elastin and have many
functions that include modulation of the assembly and interaction of collagen and elastin fibers,
modulation of ion transport through the ECM, and regulation of growth factor effects on
connective tissue cells (Zink and Van Dyke, 2013). The synthesis of PGs involves transcription
and translation of a core protein, GAG conjugation of the protein, and secretion of the mature
PGs into the extracellular environment. Existing PGs are degraded by a variety of proteases and
polysaccharides. However, PGs bio-synthesis is a highly regulated anabolic process and can be
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triggered by exposure of cells to a variety of biological mediators as well as some
pharmacological agents.
INTRODUCTION TO OSTEOARTHRITIS
Cartilage strength and function depend on both the properties of the tissue and their
structural parameters. As mentioned previously, cartilage is made up of macromolecules that are
collagen and PGs (aggrecan) that are saturated with water. The interaction of the physical and
biochemical structures of cartilage is necessary to allow the normal function of providing nearly
frictionless motion, wear resistance, joint congruence, and transmission of load to subchondral
bone. Chondrocytes are responsible for synthesizing and maintaining this material. Osteoarthritis
(OA) can be defined as a disorder of the synovial joints. It is characterized by deterioration of
articular cartilage, osteophyte formation and bone remolding, pathology of periarticular tissues
including synovium, subchondral bone, muscle, tendon, ligament, and a low-grade, nonpurulent
inflammation of a variable degree (Fox and Millis, 2010). OA occurs when there is disruption of
normal cartilage structure and homeostasis, which results from a complex interaction of
biochemical and biomechanical factors that occur concurrently and serve to perpetuate
degradative change. The changes associated with osteoarthritis ultimately have an impact on the
patient through decreased ability to use the joint or the production of pain, or both. Osteoarthritis
affects any freely movable joints of small animals including the shoulder, elbow, carpus, hip,
stifle, tarsus, and spinal articulations (Baltzer, 2008). It usually is not detected in the beginning
state, because animals will hide their weaknesses as a survival technique. Unfortunately, once
OA has begun, the progression of the disease can only be slowed but never completely stopped.
Nevertheless, understanding the basic mechanisms involved in the development and progression

5

of OA provides a basis for establishing a reasonable expectation for the patient and a rational
plan of treatment for this condition.
At the overt stage of the disease, OA chondrocytes produce higher levels of matrix
metalloproteinases (MMPs) and lower levels of cartilage matrix molecules than healthy
chondrocytes (Henrotin et al., 2004). Due to the imbalance between catabolic and anabolic
processes from the chondrocytes, cartilage loss in osteoarthritis occurs as a consequence of
enzymatic degradation of the ECM, resulting in loss of PGs (aggrecan) and cleavage of type II
collagen (Neil et al., 2005). Matrix metalloproteinase has many different substrates that are
similar in structure, but their actions on type II collagen differ. For instance, the triple helical
region of the type II collagen molecule is resistant to degradation by most proteinases, but can be
cleaved by the action of collagenases (MMP-1, -8, and -13) (Neil et al., 2005). Afterwards these
collagen fragments proteins are susceptible to being broken down into smaller protein fragments
by gelatinases (MMP-2 and -9), which are enzymes that can also degrade aggrecan (Neil et al.,
2005). Furthermore, stromelysins (MMP-3, -10, -11) are capable of degrading aggrecan directly,
type II collagen directly from the beginning of this process, and small PGs of the ECM (Neil et
al., 2005). Overall, these multiple members of the MMP family are acting together and are
responsible for the degradation of the collagen fibrils. The MMPs are zinc-dependent proteinases
involved in the normal physiologic turnover of cartilage (Neil et al., 2005). The MMPs have
naturally produced inhibitors termed tissue inhibitors of metalloproteinases (TIMPs) that help
regulate MMP activity. However, in an osteoarthritic joint, the production of TIMPs is
insufficient to control increased MMP activity that has been discussed above.
Aggrecanases appear to be the principal mediators of aggrecan degradation. Their activity
results in the release of core protein and GAG constituents of aggrecan into synovial fluid (Neil
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et al., 2005). The GAG fragments have been used as markers of cartilage loss in osteoarthritis.
Aggrecanases, like MMPs, are metalloproteinases and can be inhibited by TIMPs (Neil et al.,
2005). Martel-Pelletier et al., (2005) states that aggrecans are probably among the first cartilage
matrix constituents to be affected, as they are progressively depleted in parallel with the severity
of the disease. A decrease in aggrecan glycosaminoglycan content in the ECM can result in over
compression of the cartilage under load, causing an adverse response by the chondrocytes with
increased protease secretion and subsequent tissue degeneration.
Osteoarthritis is also associated with increased concentrations of other inflammatory
mediators such as nitric oxide and prostanoids, particularly prostaglandin E2 (PGE2). Nitric
oxide induces a number of pathophysiologic events characteristic of OA, including enhanced
MMP synthesis and reduced synthesis of interleukin-1 receptor antagonist (IL-1Ra),
proteoglycan, and type II collagen (Neil et al., 2005). Prostaglandin E2 is found in the synovial
fluid of animals with OA in increased concentrations, because arachidonic acid increases within
the joint and is the precursor of PGE2. Prostaglandin E2 has actions of vasodilation and cartilage
PG depletion. Furthermore, Neil et al., (2005) states that central to the induction of degradative
enzyme and inflammatory mediator synthesis in OA tissues are a number of cytokines, the most
important of which is interleukin-1 (IL-1). Cytokines appear to be first produced by cells of the
synovial membrane and later by activated chondrocytes. Interleukin-1 pathway (figure 1)
mediates its effects on chondrocytes through a cell membrane-associated interleukin-1-receptor
(IL-1R) (Neil et al., 2005). The IL-1 binds with IL-R and induces production of transcription
factors, such as activator protein-1 and nuclear factor kappa B. These transcription factors then
bind to binding sites of promoters of various genes and increases their transcription, including
genes such as MMP’s, inducible nitric oxide synthase, and cyclo-oxygenase-2. In general, IL-1
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acts to enhance cartilage degeneration
eneration and inhibit repair. Additionally, besides cartilage
degradation the
he synovial membrane and subchondral bone show structural changes.
changes Subchondral
bone thickening is accompanied by increased osteoid volume and a low mineralization,
mineralization
suggesting that a dysregulation of bone remodeling may be part of OA (Henrotin et al.,
al. 2005).

(Figure 1) Chondrocyte cell and tthe interleukin-1 pathway
DIAGNOSIS AND TREATMENT OF OSTEOARTHRITIS
Multiple etiologies can contribute to the formation of OA, including defective
articular cartilage structure and biosynthesis, joint trauma, joint instability, congenital and
developmental abnormalities, and infl
inflammatory conditions (Aragon et al., 2007). Osteoarthritis
affects approximately 1 in 5 adult dogs in the U.S. (Fox and Millis
Millis, 2010). It is the number one
cause of chronic pain in dogs, and approximately 10
10-12
12 million dogs in the U.S. show signs of
OA (Fox and Millis, 2010). When looking for signs of feline OA it is particularly challenging for
owners and veterinarians to identify, purportedly because signs such as overt lameness
lam
that is
noticed in dogs is rare in cats (Klinck et al.
al., 2012). Furthermore, feline radiographic images do
not correlate well
ll with expressed pain or functional impairment, thereby hindering diagnosis and
therapy (Klinck et al., 2012). Radiograp
Radiographic images are used to help diagnosis OA in companion
animals and consist of advanced im
images, such a computed tomography, magnetic resonance
imaging,, and nuclear scintigraphy. Along with radiographs a proper diagnosis depends on a
complete history and full assessment of the patient including: a complete physical, orthopedic,
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and neurologic examination, advanced gait analysis, clinicopathologic examination,
electrodiagnostic testing, muscle biopsy examination, and special tests (Fox and Millis, 2010).
The special tests include: muscle percussion, serology for pathogens, measurements of
acetylcholine receptor antibody, immunohistochemistry, and molecular diagnostic techniques
(Fox and Millis, 2010). After diagnosing an animal with OA the management of OA typically
involves a multimodal approach, which can include one or more of the following: activity
control, weight management, nutritional support, physical therapy, administration of nonsteroidal
anti-inflammatory drugs, analgesic medications, nutraceuticals, and in some cases surgery
(Aragon et al., 2007).
MEDICINAL MANAGEMENT
Medicinal management include several nonsteriodal anti-inflammatory drugs (NSAIDs),
polysulfated glycosaminoglycan (PSGAG), hyaluronic acid, and several corticosteroids,
including betamethasone, dexamethasone, triamcinolone, methylprednisolone and prednisolone
(Lees, 2003). These are available in products with veterinary marketing authorizations for
intravenous, intramuscular, oral and local (intra-articular) administration (Lees, 2003).
Nonsteroidal anti-inflammatory drugs are effective for managing acute and chronic orthopedic
pain as well as post-surgical pain (KuKanich et al., 2012). Currently, several NSAIDs (carprofen,
cinchophen, deracoxib, etodalac, firocoxib, flunixin, ketoprofen, mavacoxib, tepoxalin,
tolfenamic acid, and vedaprofen) have approval for the control of canine chronic pain (Fox,
2010). However, NSAIDs approved for feline use are far more limited (meloxicam, tolfenamic
acid, ketoprofen, robenacoxib, carprofen, and aspirin) and short administration of them depends
on the country (Fox, 2010). There are not as many NSAIDs for feline use due to the potential
risk of NSAIDs toxicity in cats. Cats are susceptible to NASIDs toxicity, because of slow
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clearance and dose-dependent elimination. They have a low capacity for hepatic glucuronidation
of NSAIDs, which is the major mechanism of metabolism and excretion for this class of drug
(Fox, 2010). However, many clinicians manage the exclusive pain of OA in dogs simply by
sequencing different NSAIDs until satisfactory patient results are found or unacceptable adverse
reactions are experienced (Fox and Millis, 2010).
The goal of NSAIDs is to inhibit PG formation that contributes to clinical signs and
pathways of OA, while sparing PG production associated with beneficial physiological
functions. This goal is achieved through NSAIDs manifesting their mode of action on the
arachidonic acid (AA) pathway (figure2). The AA pathway produces a number of different
eicosanoids, known as signaling molecules that exert control over many bodily systems, mainly
in inflammation, or immunity, and as messengers in the central nervous system. There are four
families of eicosanoids: the prostaglandins, prostacyclins, thromboxanes, and leukotrienes. Two
enzymes catalyze fatty acid oxygenation to produce these eciosanoids. One of the enzymes is
cyclo-oxygenases (COX) which generate prostaglandins, prostacyclins, thromboxanes, and are
referred to as prostanoids. Furthermore, the other enzyme lipoxygenase generates leukotrienes.
Normally, in the body, prostaglandins, specifically PGE2, have many beneficial roles, but during
the progression of OA PGE2 takes on a more damaging role. Some of those damaging roles of
PGE2 include: lowering the threshold of nociceptor activation, promoting synovitis in the joint
lining, enhancing the formation of degradative matrix metalloproteinases, and depressing
cartilage matrix synthesis by chondrocytes (Fox and Millis, 2010). In contrast, some of the
beneficial roles of PGE2 are; enhancing platelet aggregation to prevent excessive bleeding,
maintaining integrity of the gastrointestinal tract, and facilitating renal function (Fox and Millis,
2010). Certain NSAIDs act to inhibit both cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2
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(COX-2) (eg. aspirin, ketoprofen, ketorolac) while other NSAIDs preferentially inhibit COX-2 or
are COX-1 sparing in various degrees (eg. meloxicam, carprofen, etodolac, tolfenamic acid)
(Mathews, 2002). These two enzymes are what cause beneficial and damaging roles that have
been described above. COX-1 is responsible for the beneficial roles of PGs and COX-2 is
responsible for the damaging roles of PGs. KuKanich et al., (2012) describes a COX-1/COX-2
inhibitory ratio, also known as the IC50 ratio, which is defined as the concentration of the drug
(NSAID) needed to inhibit the activity of both enzymes COX-1 and COX-2 by 50%. This ratio
has a high concentration of NSAID before causing 50% inhibition of COX-1 and a low
concentration of NSAID to reach the IC50 for COX-2 (Fox and Millis, 2010). Therefore, the
higher the numerator and lower the denominator the higher the absolute value is in creating a
greater COX-1/COX-2 ratio. Thereafter, a greater COX-1/COX-2 ratio theoretically will create a
more optimal performing NSAID (Fox and Millis, 2010). However, animals that have been
administered NASIDs may have adverse effects that occur in the gastrointestinal tract (GI), in
the kidneys, or the liver.

(Figure 2) Arachidonic Acid pathway

Nonsteriodal anti-inflammatory drugs can irritate the GI mucosa directly when
administrated orally or following secretion in bile regardless of administration type because
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many NSAIDs are weak acids. Gastrointestinal adverse effects can range from vomiting,
anorexia and diarrhea to mild gastritis and severe gastrointestinal ulceration, bleeding and death
(KuKanich et al., 2012). Prostaglandins E2 and prostacyclin I2 (PGI2) have important gastroprotective effects including mucosal blood flow, increased mucus production, increased
bicarbonate production, decreased acid secretion and increased turnover of gastrointestinal
epithelial cells (KuKanich et al., 2012). A domino effect occurs through the inhibition of both
COX-1 and COX-2, which affects PGE2 and PGI2, which then causes adverse GI tract effects
within an animal.
In contrast to inhibition of both COX enzymes, it has been suggested that inhibition of
COX-1 or COX-2, exclusively, results in minimal GI adverse effects (Wallace et al., 2000). This
suggestion is thought to be due to an up-regulation of the COX enzyme that is not being
inhibited since both COX-1 and COX-2 produce PGE2. Furthermore, it appears that recently
licensed veterinary NSAIDs have a decreased frequency of GI tract adverse effects in dogs
compared to drugs such as aspirin, ketoprofen, phenylbutazone, tolfenamic acid, and flunixin
(Reimer et. al., 1999; Nishihara et. al., 2001; Luna et. al., 2007). A study on research dogs was
conducted for 90 days and results concluded that ketoprofen, flunixin, and etodolac produced
greater gastric lesion scores than the placebo (lactose), carprofen, and meloxicam (Luna et al.,
2007). Moreover, another study observed greater GI lesions after aspirin administration
compared to carprofen and etodolac in healthy experimental dogs (Reimer et al., 1999). With
that said, it is also believed that some NSAID drugs may lose the COX-1 sparing effect at high
doses and the frequency of GI tract adverse effects will increase (Peterson and Cryer, 1999). A
study conducted using the NSAID etodolac at higher doses caused GI lesions (2.7x label dose) or
death (5.3x label dose) (KuKanick et al., 2012). Similarly, in another study meloxicam has also
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been associated with GI toxicity at higher doses (Reed, 2002; Enberg et. al., 2006). In addition to
GI adverse effects animals may also experience adverse effects of the kidneys.
Prostaglandin E2 and PGI2 also aid in some normal functions of the kidneys.
Prostaglandin E2 and PGI2 alter kidney physiology by increasing sodium excretion, inhibiting
sodium reabsorption, and altering chloride transport (Simmons et al., 2004). They also stimulate
renin release and alter total renal blood flow and regional blood with the kidneys of dogs
(Simmons et al., 2004). Furthermore, studies have suggested that high doses of NSAIDs, sodium
depletion, hypotension (decreased or low blood pressure), hypovolemia (reduction in volume of
blood), and anesthesia appear to increase the risks of renal adverse effects. Data et al., (1976),
conducted a study examining the impact of high doses (6x dose label) of aspirin on renal blood
flow. The results suggested that the predominant acute effects of aspirin on the kidneys were a
decrease in total renal blood flow and altered distribution of renal blood flow within the renal
cortex. Another study was conducted on hypovolemic dogs with high doses of aspirin (100
mg/kg) compared to hypovolemic dogs without aspirin treatment. Hypovolemic dogs treated
with high doses of aspirin had a significantly decreased total renal blood flow and the
distribution of blood flow in the cortex was decreased in all areas (Papich, 2007). In contrast,
dogs without aspirin treatment only had a slightly decreased total renal blood flow, but
distribution of blood flow was markedly altered with increased blood flow to the regions of the
cortex closest to the medulla (Papich, 2007). Other studies have examined the effects of
meclofenamate (a nonselective COX inhibitor), nimesulide (a COX-1 sparing NSAID),
indomethacin (a nonselective COX inhibitor), carprofen (a COX-1 sparing NSAID), ketorolac (a
presumptive nonselective COX inhibitor in dogs), and ketoprofen (a nonselective COX inhibitor)
on the renal physiology of dogs. Meclofenamate significantly decreased renal blood flow and
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altered redistribution of renal blood flow within the renal cortex during renal hypotension in dogs
(Opgenorth et al., 1987). In contrast, a separate study Rodrı´guez et al., (2000) also administered
meclofenamate and observed decreased renal blood flow without alteration of glomerular
filtration rate in dogs, suggesting that glomerular filtration rate is not an appropriate indicator of
acute NSAID induced renal effects. Nimesulide had minimal effects on renal blood flow in
normal dogs, but dogs that were sodium depleted experienced a significant decrease in renal
blood flow again without significant effects on the glomerular filtration rate (Rodrı´guez et al.,
2000). Indomethacin, administered to anesthetized dogs significantly decreased renal blood flow
and decreased sodium excretion, but had no effect on the glomerular filtration rate (Feigen et al.
1976). Another study by Frendin et al., (2006) studied the effects of NSAID carprofen on renal
blood flow in anesthetized animals. The treatment of carprofen significantly decreased renal
blood flow during anesthesia (about 50% compared to pretreatment values). Lastly, Lobetti et al.,
(2000) conducted a study using carprofen at 4 mg/kg, ketorolac at 0.5 mg/kg, and ketoprofen at 1
mg/kg were compared to morphine at 0.1 mg/kg in 40 dogs undergoing ovariohysterectomy.
This study did not measure renal blood flow, but the NSAID treated dogs experienced significant
effects manifested by decreased renal sodium excretion compared to baseline values. Overall,
these studies have shown that animals are at higher risk of renal adverse effects during the
administration of high doses of NSAIDs, sodium depletion, hypotension (decreased or low
blood pressure), hypovolemia (reduction in volume of blood), and during anesthesia. However,
healthy dogs administered approved doses of NSAIDs are at low risk for renal adverse effects
(KuKanick et al., 2012).
Lastly, NSAIDs adverse effects in the liver have the lowest percentage of occurrence at
14%, while reactions in the GI tract are 64% and in the renal system are 21% (Fox and Millis,
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2010). Adverse effects of NSAIDs on the liver can be divided into two groups; dose-dependent
toxicity and dose-independent toxicity (Mensching and Volmer, 2009). Dose-dependent toxicity
for example occurs within an animal due to massive overdosing of NSAIDs and doseindependent toxicity typically occurs within an animal that is administered the correct label dose
of NSAIDs. One NSAID called firocoxib has been associated with fatty liver changes in young
dogs at high doses (KuKanick et al., 2012). Another study investigated adverse effects of long
term administration of several different NSAIDs (carprofen, etodolac, flunixin, ketoprofen and
meloxicam) in dogs (Luna et al., 2007). This study concluded only minor and clinically
insignificant changes occurred in serum biochemical variables. Another study evaluated the long
term effects of NSAIDs on 805 client owned dogs of different breed, ages and body weight.
Carprofen was administered for 84 days and 3.2 % of the dogs left the study due to adverse liver
effects, with the majority leaving within the first 3 weeks (Mansa et al., 2007). MacPhail et al.,
(1998) suggested that most NSAID-associated hepatopathies occur within the first 3 weeks of
treatment. Lastly, KuKanick et al., (2012) reported that long-term administration of firocoxib to
1002 dogs with OA was well tolerated with only 5% of dogs leaving the study due to adverse
effects of any kind. These studies suggest that long-term NSAID administration is not associated
with hepatocellular toxicity. However, these studies are the basis of recommendations for more
intensive monitoring during the early stages of NSAID administration (KuKanick et al., 2012).
Another concern to be aware of is there are very few studies describing the use of
NSAIDs in animals with underlying hepatic disease and no data indicating that animals with
hepatic disease are at an increased risk of NSAID hepatic toxicity (KuKanich et al., 2012).
However, animals with underlying hepatic disease may have decreased excretion ability of
NSAIDs from the body since NSAIDs are primarily eliminated by hepatic mechanisms, but this
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may be drug and disease specific (KuKanich et al., 2012). Holazo et al., (1985) and Brater and
Lasseter, (1989) conducted a study in humans with liver dysfunction due to hepatic cirrhosis
compared to healthy individuals. They stated that the elimination of carprofen and etodolac were
not altered in either study group. However, it is unclear if similar pharmacokinetics of carprofen
or etodolac occur in dogs with and without liver disease (KuKanick et al., 2012). With this
stated, it is unclear if the dose of an NSAID needs to be decreased for an animal with preexisting hepatic disease. Prior to instituting any NSAID drug or any other medicinal therapy a
complete medical examination and physical examination has to be conducted. It is prudent to
determine baseline renal and hepatic panels by clinical chemistries before administration of any
drug, which is then followed up by repeat testing within two weeks and periodically after that.
These periodic tests will inform the veterinarian of trends as well as absolute values and any
unexplained increase in renal or hepatic enzymes. Along with NSAIDs, PSGAG and
corticosteroid products are also medicinal drugs used to help the symptoms of an animal with
OA.
A polysulfated glycosaminoglycan is considered to be a disease modifying osteoarthritic
drug. Polysulfated glycosaminoglycans have been stated to protect articular cartilage from
degradative enzymes as well as stimulate chondrocytes to produce normal components of
articular cartilage (Baltzer, 2008). Specifically, Adequan is a PSGAG drug that is commercially
available for animal use. The licensed PSGAG Adequan has been reported to be most effective
when administrated in the early stages of OA. The reason for administrating this drug during the
early stages of OA is to delay medically-aggressive treatment as long as possible during the
progression of OA (Fox and Millis, 2010). Overall, PSGAG activity reduces proteoglycan
degradation through inhibiting synthesis and activity of aggrecanases, MMPs, nitric oxide, and
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PGE2, stimulates GAG synthesis through chondrocytes, and increase hyaluronan concentrations
by synovial membrane cells (Fox and Millis, 2010). Therefore, PSGAGs are characterized as
being a disease modifying or chondroprotective OA drug.
Another medicinal drug that is given to OA patients are corticosteroids. Corticosteriods
are steroids that can be administrated orally or through injection. However, steroid injection in
dogs is usually reserved for severe cases that have become non-responsive to other treatments
and the animal is suffering and its quality of life is an issue (Henrotin et al., 2005). However, in
contrast an in vivo study has suggested that corticosteroids have been shown to have a
prophylactic effect on OA lesions, suggesting that they could also be used earlier in the disease
process (Pelletier et al., 1989). In this study, twenty-four dogs had their anterior cruciate
ligament (ACL) surgically sectioned. Six were treated with oral prednisone, 6 were treated with
intra- articular injections of triamcinolone hexacetonide, at surgery and 4 weeks later, and
tweleve dogs received no treatment. Results from this study indicated that untreated dogs
developed significant cartilage lesions with prominent osteophytes, while operated dogs treated
orally or with intra-articular injections had a significant reduction in osteophyte size. Cartilage
erosions were observed in 25% of the untreated dogs, 8% of the dogs receiving oral prednisone,
and none of the dogs receiving intra-articular triamcinolone hexacetonide. Therefore,
corticosteroids significantly reduced the severity of OA structural changes of the cartilage in
animals with surgically induced ACL injuries.
NUTRACEUTICAL MANAGEMENT
Another approach to the treatment of OA is through the use of nutraceuticals. The North
American Veterinary Nutraceutical Council defines nutraceuticals as a nondrug substance that is
produced in a purified or extracted form and administrated orally to provide agents required for
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normal body structure and function with the intent of improving the health and well-being of
animals (Bauer, 2001). There are more than thirty products that have been listed as being
potentially beneficial for OA patients. Next to NSAIDs management, the uses of nutraceuticals
are one of the fastest growing groups of health care products for human and animal use. The
main nutraceutical compounds of interest are glucosamine (GlcN), glucosamine hydrochloride,
glucosamine sulphate, chondroitin sulphate, and a combination of glucosamine hydrochloride
and chondroitin sulfate.
Glucosamine is an amino sugar that is essential for the biosynthesis of glycosylated
proteins and lipids. It also is a major constituent of extracellular matrix macromolecules such as
glycosaminoglycans, glycolipids, and glycoproteins in its acetylated form, and is present in high
quantities in articular cartilage, intervertebral disc, and synovial fluid (Henrotin et al., 2012). A
primary theory suggested that when an exogenous form of GlcN is supplemented it provides the
body with building blocks that are lacking for the synthesis of GAGs by chondrocytes. Various
studies however have concluded that GlcN causes a reduction in proteoglycan degradation and
inhibition of the synthesis and activity of degradative enzymes and inflammatory mediators such
as aggrecanases, MMPs, nitric oxide, and PGE2 (Sandy et al. 1998; Fenton et al., 2002; Bryon et
al., 2003). Furthermore, anabolic effects are limited to stimulation of GAG and proteoglycan
production in aggrecan, but do not affect type II collagen (Busci and Poor, 1998). Furthermore,
two in vitro studies concluded that high doses of GlcN may have detrimental effects on
chondrocytes viability (Anderson et al., 1999; de Mattei et al., 2002). Ilic et al., (2003) also
concluded that long-term exposure of GlcN had no detrimental effect on chondrocyte
metabolism. However, another in vitro study administrating high doses of GlcN Fenton et al.,
(2000) failed to observe effects on chondrocyte viability, but concluded that a protective action
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against cytokine-induced catabolic effects was maintained. Other studies Gouze et al., (2002);
Largo et al., (2003) have also concluded that GlcN has a protective action against cytokineinduced catabolic effects, specifically by reduction in transcription factors involved in the
intracellular signaling of IL-1. Transcription factors activator protein-1 and nuclear factor kappa
B increase in cartilage during OA and these two factors stimulate the transcription of genes that
play a vital role in cartilage degradation, such as COX, inducible nitric oxide synthase, and
MMPs. Glucosamine appears to inhibit nuclear factor kappa B transcription activity and nuclear
translocation, but has no effect on activator protein-1 (Largo et al., 2003). Furthermore, Gouze et
al., (2002) concluded that glucosamine increases the expression of a decoy receptor that reduces
binding of IL-1 to its receptor. Thus, the actions of glucosamine appear to have an anti-catabolic
potency seen by its inhibition of the expression or activity of catabolic enzymes that are
unregulated by OA.
In the body GlcN normally is in the form of glucosamine-6-phosphate, but GlcN is
commercially available in four forms: glucosamine hydrochloride, glucosamine sulfate, Nacetyl-D-glucosamine, and a combination of glucosamine hydrochloride and chondroitin sulfate.
The type of formulation of GlcN influences the activity, with glucosamine hydrochloride and
glucosamine sulfate inhibiting cartilage degeneration more consistently than N-acetyl-Dglucosamine in vitro (Fox, 2010). When comparing GlcN to chondroitin sulfate the mechanism
of action is similar, but not identical. Chondroitin sulfate also stimulates GAG synthesis and
inhibits degradative enzyme synthesis, including MMPs (Ronca et al., 1998; Orth et al., 2002).
However, chondroitin sulfate effects PGE2 and nitric oxide production to a greater degree and
chondroitin sulfate is unique in its ability to improve synovial fluid viscosity by increasing
hyaluronic acid concentrations (Bassler et al., 1998). Furthermore, chondroitin sulfate inhibits
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IL-1 induced type II collagen degeneration while GlcN does not. There have been several
companion animal clinical trials and experimental models that used a combination of
glucosamine hydrochloride and chondroitin sulfate. The results of two trials conducted on dogs,
suggested a cartilage sparing effect due to a reduction in severity of OA lesions (Hulse et al.,
1998; Lippiello et al., 2000). Results of another study conducted on dogs concluded both
preventative and therapeutic effects in the experimental models of osteoarthritis (Canapp et al.,
1999). Furthermore, two other studies showed improvement in clinical signs as well as synovial
fluid variables, serum GAG content, and articular cartilage metabolism improved, therefore
suggesting a more normal synovial environment (Hardingham, 1998; Johnson et al., 2001).
One can see that GlcN has produced various effects in different in vivo and in vitro
models. Trials have been conducted under different conditions, with different formulations and
dosages, showing a tendency to produce a protective effect on articular tissues. However,
nutraceuticals being classified as a dietary supplement by the FDA are not subject to strict
regulatory guidelines. Therefore, commercially available products may vary widely in terms of
purity and quality. Russel et al., (2002) concluded that human over the counter products vary
considerable in composition, and another study stated that greater than 84% do not meet the label
claim (Adebowale et al., 2000). Furthermore, a combined product of glucosamine and
chondroitin was studied (Ramey et al., 2002). Results stated that GlcN content was 86% and
chondroitin sulfate content was 83.3% of the label claim. Products are often marketed with a
guaranteed analysis, however only a few products consistently meet their label claim (Liang et
al., 1999; Adebowale et al., 2000; Liang et. al., 2002). Veterinary product efficacy in vivo or in
vitro studies are limited and claims of efficacy are often made on the basis of subjective methods
of assessment, including testimonials by owners or clinical trials that have not been subjected to
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peer review (Neil et al., 2005). However, despite this issue nutraceutical products continue to
gain popularity.
Part of the attraction to nutraceuticals is their potential use as an alternative to other drugs
such as NSAIDs that are currently used for OA management. A study reported that NSAIDs
administration resulted in prompt reduction of clinical signs, but signs reappeared after cessation
of treatment (Morreale et al., 1996). This study was compared with animals treated with
chondroitin sulfate who showed a delayed onset of effectiveness, but had a greater duration of
clinical sign reduction (3 months) after treatment with chondroitin sulfate had been stopped (Neil
et al., 2005). With the evidence that certain nutraceuticals are relieving OA symptoms longer
than NSAIDs and that there have been no serious or adverse effects reported with GlcN, further
studying of these nutraceuticals could open a new horizon for OA patients. Furthermore, since
there has not been any serious or adverse effects reported from randomized controlled trials of
GlcN, there are still potential side effects that should be kept in mind. The first side effect that
OA patients should be aware of is the possibility of having an allergic reaction, commonly called
a shellfish allergy. GlcN is extracted from chitin contained in shellfish and could lead to an
allergic reaction (Henrotin et al., 2012). Secondly, GlcN sulfate is administrated as a salt
combined with NaCl, which provides up to 30% of the daily intake of salt (Henrotin et al., 2012).
Also, this has to be taken into account, because Na and Cl could have an effect on blood pressure
and renal function. Lastly, some human and animal studies have suggested that GlcN can affect
glucose metabolism and it has been shown to induce insulin resistance (Henrotin et al., 2012).
However, a recent report by a GlcN manufacturer has concluded that GlcN had no effect on
fasting blood glucose levels, glucose metabolism, or insulin sensitivity at any oral dose level in
healthy subjects, individuals with diabetes, or those with impaired glucose metabolism (Henrotin
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et al., 2012). The lack of reported adverse effects could be due to the short duration of exposure,
so further studies are warranted to determine the long term effects of GlcN. Therefore, until these
trials are conducted OA patients that are diabetic or hypertensive should undergo treatment
cautiously. Also, based on the fact that GlcN has low and rare adverse effects, it represents a
viable option for the management of OA as a symptomatic slow-acting drug, but that
administration should be discontinued if no significant effect is reported (Henrotin et al., 2012).
Following medicinal and nutraceutical treatment, physical rehabilitation is another step to the
multimodal treatment of OA animals.
PHYSICAL REHABILITATION MANAGEMENT
Traditional management of dogs with OA has included anti-inflammatory and analgesic
drugs, changes in lifestyle, and surgical management. More recent advances in the management
of OA include weight loss, therapeutic exercise, and physical modalities to reduce the severity of
clinical signs and the reliance on medications to control pain and discomfort (Millis et al., 2005).
Therapeutic rehabilitation helps reduce body weight if needed, increases joint mobility, and
reduces pain through the use of low-impact exercises designed to strengthen supporting muscles,
as well as building up daily function. A complete physical examination is necessary to develop a
successful physical therapy regime. It should include a clinical orthopedic and neurological
examination (Bockstahler, 2006). Each therapist involved in the physical therapy treatment
should have a comprehensive knowledge of the clinical features and treatment of the underlying
disease, and to avoid any aggravation of the symptoms by inadvertently selecting inappropriate
methods.
The weight of an OA animal should be addressed, because obesity in humans and
animals is strongly associated with the development of OA. Obesity is a likely contributor to the
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progression of OA, due to the immense exertion put on joints, tendons and ligaments. Weight
reduction of 11% to 18% of the initial body weight of obese dogs resulted in significant
improvement of hind limb lameness associated with hip OA in one study (Millis et al., 2005). To
achieve weight reduction, treats should be eliminated from the diet along with implementing a
special formulated prescription diet. In general, the weight reduction goal is to reduce fat
composition to 20-25% of an animal’s total body weight (Millis et al., 2005). The weight loss
program and physical therapy should be started at the same time. The success of therapy will
greatly depend on setting up an exercise program individually designed for the animal and its
owner.
There are various types of physical exercises that are used to create a physical therapy
program to reach the goals of weight loss and to increase mobility and strength. Some examples
of exercises used are: slow leashed walks, walking or jogging, stair climbing, sit to stand
exercises, and additional use of balance board, swiss balls, and physiorolls (Bockstahler, 2006).
These programs also use various exercise equipment: balancing boards, swiss balls, and
physiorolls. Perhaps the most important exercise equipment that can be implemented is the use
of an underwater treadmill, because the physical properties of water can be utilized for the
physical therapy. The body bears less weight in water and permits a pain free and more
comfortable movement of joints and the water resistance is useful for muscle strengthening and
cardiovascular training (Bockstahler, 2006). However, the most recommended exercise for dogs
is to take several short walks throughout the day rather than one long forced walk. By doing this
you can assess how long the animal can exercise without feeling pain. The daily exercise period
can be increased by 10% per week. If the animal starts to experience pain while exercising, the
exercise rate has to be reduced by at least 30%. In general, cats can gain advantages from
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physical therapy, but the treatment protocol needs to be adapted to the behavior and handling
potential. For example, the motion exercises should involve their natural play instinct, such as
playing with a toy or laser pointer. For the most part therapies like range of motion exercises and
stretching can be performed on cats, and massaging is also well accepted by them (Bockstahler,
2006). Before an animal starts any of these exercises thermotherapy (the use of warming agents
and cryotherapy (the use of cooling agents) should be conducted along with massaging of the
joints. The use of warming agents on OA tissue promotes blood to flow to the area, promotes
tissue and collagen extensibility, decreases pain and muscle spasms, and joint stiffness (Millis et
al., 2005). Heating agents that can be used are moist or dry hot packs, circulating warm water
blankets, warm baths for distal joints (toes, carpus, tarsus, stifle or elbow), or therapeutic
ultrasound (US) for heating of deeper joints (hip, shoulder, or vertebral joints). Most therapeutic
ultrasound equipment currently offers two frequencies: 1 MHz (low-frequency) and 3 MHz
(high-frequency) and two modes of utilization are possible: continuous and pulsated. Therapeutic
ultrasound has four important biological properties and therapeutic effects. Ultrasound waves can
penetrate biological tissue 5 cm in depth and can increase tissue temperature from +1 - +4
degrees Celsius. They also have effects related to their vibratory properties, which results in
micro-massages that modify membrane permeability stimulating angiogenesis, increasing the
release of growth factors, and promoting the proliferation of fibroblasts and collagen production
(Sawaya, 2007). Lastly, ultrasound waves increase skin permeability, which encourages the
passive diffusion of drugs into deep tissue (Sawaya, 2007). Cryotherapy is used to decrease
blood flow, reduce inflammation, and slow metabolic rate (Millis et al., 2005). The cooling
agents that can be used are cold packs or ice wrapped in a towel. The administration of a cooling
agent can also be used during an exercise if inflammation is detected to prevent swelling and
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pain. Massaging of the osteoarthritic area is important in both warm and cooling down period,
because it aids in the release of muscle tension, improves blood and lymphatic circulation, and
increases muscle flexibility. All hand grip massaging techniques, like stroking, kneading, or
circulation pressure, which are well-known from classical human massage techniques, can also
be used in companion animals (Bockstahler, 2006). Along with thermotherapy, cryotherapy, and
physical therapy there are two other therapies that can be administrated that involve electrical
stimulation.
The first that has been around the longest is called transcutaneous electrical nerve
stimulation (TENS) used on companion animals. It is the most common method used in physical
therapy and the two modalities that are currently used are called the gate control TENS and
endorphinic TENS. Gate control TENS is, peripheral hyper-stimulation of large caliber sensitive
fibers at high-frequency (generally 80 or 100 Hz, sometimes even 200 Hz for intense pain),
which inhibits the transmission of pain influxes conveyed by small-caliber fibers in the dorsal
horn of the spinal cord (Sawaya, 2007). The intensity of the current must remain beneath the
threshold of motor neuron stimulation, which means it should not trigger muscular contraction.
This type of current generates rapid, but short (one to several hours) analgesia, and is indicated
mainly for acute and super-acute pain. Endorphinic TENS is stimulation of small-caliber fibers,
at very low frequency (2 to 8 Hz), which favors the release of endorphins and encephalins in the
encephalon (Sawaya, 2007). The current intensity is just above the muscular contraction
threshold and provides gradual and longer-lasting pain relief (sometimes up to 8 hours).
Endorphinic TENS is indicated for sub-acute and chronic pain. Another electrical stimulation
therapy is called extra-corporeal shock wave therapy (ESWT) and is relatively a new
physiotherapy treatment for canines. Good results in using ESWT have been reported by several
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veterinarians, but the number of controlled clinical studies is still very limited (Bockstahler,
2006). This therapy uses very short waves emitted at low frequency and under very high
pressure. These waves have very high energy and are characterized by a peak of very high
overpressure (up to 100 times atmospheric pressure), followed by a trough, and occurs
approximately within a microsecond. The theory behind ESWT mode of action is that short-term
pain reduction may be based on a release of endorphins and long-term pain relief may be caused
by mechanical and chemical effects on a cellular level where shockwaves can stimulate both the
healing process and the modulation of pain signals (Bockstahler, 2006). It has been observed that
ESWT is effective in reducing pain rapidly, has a sustainability (pain relieved from several
weeks to months), and has improved mobility and quality of life for arthritic dogs (Sawaya,
2007). Furthermore, electrotherapy in general can be a possible treatment administrated to cats.
In the treatment of cats and dogs the involvement of the pet owner is especially
important. In companion animals, especially those with chronic disorders, it is absolutely
necessary to inform the owner that life-long treatment is often required along with a treatment
plan. This is important, to improve the compliance of the owner and to clarify the prognosis of
the treatment (Bockstahler, 2007). A lot of the physical exercises can be conducted at home, like
some of the easy hand grip massages, range of motion exercises, and TENS therapy. It is
imperative that the owner plays an active role for the success of the animal and that these
treatments are compatible with the owner’s work schedule. Furthermore, there most likely will
have to be home environment modifications for the osteoarthritic animal if possible.
Osteoarthritic animals show decreased daily functions like climbing stairs, jumping into the car,
getting into bed, or using a litter box. Ramps or wider steps can be installed to aid with climbing
into bed, vehicles, or litter boxes. During a cold season slippery grounds can often be an obstacle
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for OA animals and the use of inexpensive carpeting can be a temporary solution. Whenever,
possible animals should be moved from a cold, damp outdoor environment to a warm, dry inside
environment. Their sleeping area should be soft and warm, but firm enough that the animal can
get up easily. The use of a circulating warm-blanket under the blankets provides heat that may
reduce morning stiffness. Pet owners may have more free time during the weekends and
overdoing activities during the weekend should be avoided. Overall, good owner-education
together with regular appointments in the clinic enables quick rehabilitation and improvement of
the clinical signs in companion animals.
SUMMARY
Osteoarthritis is an important subject for companion animals, because of its
prevalence in companion animals and its progressive nature. It has been noted that approximately
1 in 5 adult dogs in the U.S. are diagnosed with OA, approximately 10-12 million dogs in the
U.S. show signs of OA, and it is the number one cause of chronic pain in dogs. However, cats are
difficult to diagnosis because they are good at hiding signs of lameness in the veterinarian’s
office and also there is not a correlation between radiographic images and expressed pain or
functional impairment. Osteoarthritis is a progressive disease that occurs from the imbalance of
catabolic and anabolic metabolism within a joint and once homeostasis of the joint is disturbed
there is no cure. Also, it is the most common form of arthritis in companion animals. Clinical
signs in cats can be noticed at home by owners which may include; change of attitude (irritably,
especially when touched in tender areas), sleeping or resting more than in the past, reluctance to
groom, difficulty getting in or out of the litter box, and difficulty jumping up or down of
furniture. Clinical signs in dogs can include; change of attitude (guarding a particular joint),
slowing down of daily activity, refraining for using steps, limping, resting more, and stiffness
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and lameness (more apparent after a nap or in the morning). The most optimal treatment for
osteoarthritic animals is through a multimodal approach. That multimodal approach can be
conducted through the use of: medicinal drugs (NSAIDs, PSGAG, and corticosteroids),
nutraceuticals (different GlcN formulations), and physical therapy rehabilitation. All of these
steps of treatment are important, especially beginning PSGAG and nutraceuticals early on in the
progression of the disease, since they are most effective during the mild to moderate stages of
OA. While a strict treatment regime will not cure the animal, it may help slow-down the
progression and control the amount of chronic pain. Overall, the animal’s quality of life is at
heart and being able to improve it is every animal lover’s wish.
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